Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus - 25/08/11
, Elisabeth Rey, PharmD a, Jérôme Dimet, PharmD a, Maria Fouché, RN b, Ghislaine Firtion, MD b, Gérard Pons, MD, PhD a, Laurent Mandelbrot, MD, PhD c
Reprint requests: Jean-Marc Tréluyer, MD, PhD, Pharmacology, Hôpital Cochin-Saint Vincent de Paul, 82, avenue Denfert Rochereau, 75674 Paris Cedex 14, France.Abstract |
Objective |
The purpose of this study was to investigate placental transfer and amniotic fluid concentrations of protease inhibitors when they are given to pregnant women who are infected with human immunodeficiency virus.
Study design |
Fifty-eight mothers who received antiretroviral therapy that included ≥1 protease inhibitors for clinical indications at the time of delivery were enrolled in the study. Maternal blood samples and amniotic fluid were obtained during delivery or cesarean delivery, and paired cord blood samples were obtained by venopuncture immediately after the delivery. Drug concentrations were measured with high performance liquid chromatography.
Results |
Most maternal protease inhibitor plasma concentrations (38/66 concentrations) were below the trough concentrations that are recommended for therapeutic drug monitoring. Cord blood concentrations were below the assay limit of detection in 10 of 40 samples for nelfinavir and 25 of 40 samples for its metabolite M8, 9 of 11 samples for ritonavir, 4 of 6 samples for indinavir, 5 of 6 samples for saquinavir but were detectable in 3 of 3 samples for amprenavir. Among the 24 amniotic fluid samples that were available, the concentrations below the detection limit were 10 of 16 samples for nelfinavir, 11 of 16 samples for M8, 1 of 3 samples for indinavir, 4 of 4 samples for ritonavir, and 0 of 1 samples for amprenavir. There were significant correlations between cord blood and maternal concentrations of nelfinavir and its metabolite M8.
Conclusion |
Placental transfer of the human immunodeficiency virus protease inhibitors is generally low; however, it may differ greatly according to the molecule.
Le texte complet de cet article est disponible en PDF.Keywords : Human immunodeficiency virus, Protease inhibitor, Placental transfer, Amniotic fluid
Plan
Vol 191 - N° 2
P. 558-562 - août 2004 Retour au numéro
Article précédent
- Quantification of fetomaternal hemorrhage: a comparative study of the manual and automated microscopic Kleihauer-Betke tests and flow cytometry in clinical samples
- Denise M. Pelikan, Sicco A. Scherjon, Wilma E. Mesker, Godelieve M. de Groot-Swings, Geeske G. Brouwer-Mandema, Hans J. Tanke, Humphrey H. Kanhai
- Homocysteine thiolactone induces apoptosis in cultured human trophoblasts: a mechanism for homocysteine-mediated placental dysfunction?
- Atiwut Kamudhamas, Liyi Pang, Steven D. Smith, Yoel Sadovsky, D.Michael Nelson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?